A higher dose of semaglutide with patent pressure quickly gets the FDA

Novo Nordisk’s higher-dose semaglutide is coming soon, but the bigger story is where it marks the obesity, pricing and longevity market. The company behind Wegovy, Novo Nordiskscored a quick US regulatory win for a higher-dose version of its blockbuster obesity…












